According to this concept, we speculate that inducing 15-PGDH signalling via CysLT2R activation in CRC patients might lead to new treatment opportunities52 and better clinical outcomes by downregulating GLI1 and hence guiding the cancer cells into a more redifferentiated state. This evidence concerns the gene GLI1 and cancer.